Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Charles S Dai"'
Autor:
Lorenzo Gerratana, Andrew A. Davis, Marko Velimirovic, Katherine Clifton, Whitney L. Hensing, Ami N. Shah, Charles S. Dai, Carolina Reduzzi, Paolo D’Amico, Firas Wehbe, Arielle Medford, Seth A. Wander, William J. Gradishar, Amir Behdad, Fabio Puglisi, Cynthia X. Ma, Aditya Bardia, Massimo Cristofanilli
Publikováno v:
Breast Cancer Research, Vol 25, Iss 1, Pp 1-12 (2023)
Abstract Background although being central for the biology and druggability of hormone-receptor positive, HER2 negative metastatic breast cancer (MBC), ESR1 and PIK3CA mutations are simplistically dichotomized as mutated or wild type in current clini
Externí odkaz:
https://doaj.org/article/e709c732d873422f9a1a421cdc570023
Autor:
Arielle J. Medford, Lauren Oshry, Baris Boyraz, Lesli Kiedrowski, Sofia Menshikova, Anna Butusova, Charles S. Dai, Tasos Gogakos, Jennifer C. Keenan, Rachel H. Occhiogrosso, Phoebe Ryan, Jochen K. Lennerz, Laura M. Spring, Beverly Moy, Leif W. Ellisen, Aditya Bardia
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Tissue-agnostic indications for targeted therapies have expanded options for patients with advanced solid tumors. The Food and Drug Administration approvals of the programmed death-ligand 1 inhibitor pembrolizumab and the TRK inhibitors larotrectinib
Externí odkaz:
https://doaj.org/article/0f878bea311645418f813ed4267b5a68
Autor:
Andrew A. Davis, Lorenzo Gerratana, Katherine Clifton, Arielle J. Medford, Marko Velimirovic, Whitney L. Hensing, Leslie Bucheit, Ami N. Shah, Paolo D'Amico, Carolina Reduzzi, Qiang Zhang, Charles S. Dai, Elyssa N. Denault, Nusayba A. Bagegni, Mateusz Opyrchal, Foluso O. Ademuyiwa, Ron Bose, William J. Gradishar, Amir Behdad, Cynthia X. Ma, Aditya Bardia, Massimo Cristofanilli
Publikováno v:
EBioMedicine, Vol 86, Iss , Pp 104316- (2022)
Summary: Background: Limited data exist to characterise molecular differences in circulating tumour DNA (ctDNA) for patients with invasive lobular carcinoma (ILC). We analysed metastatic breast cancer patients with ctDNA testing to assess genomic dif
Externí odkaz:
https://doaj.org/article/07b125b3c92b42acba72a92a3f8e5d48
Autor:
Lorenzo Gerratana, Andrew A. Davis, Marko Velimirovic, Carolina Reduzzi, Katherine Clifton, Leslie Bucheit, Whitney L. Hensing, Ami N. Shah, Tania Pivetta, Charles S. Dai, Paolo D'Amico, Firas Wehbe, Arielle Medford, Seth A. Wander, William J. Gradishar, Amir Behdad, Cynthia X. Ma, Fabio Puglisi, Aditya Bardia, Massimo Cristofanilli
Publikováno v:
JCO Precision Oncology.
PURPOSE As the continuation beyond progression (BP) of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) is becoming increasingly attractive for the treatment of patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::293e3bc386f821cc9a670a7efcfddf27
https://doi.org/10.1200/po.22.00531
https://doi.org/10.1200/po.22.00531
Autor:
Marko Velimirovic, Lorenzo Gerratana, Andrew A Davis, Whitney L Hensing, Katherine Clifton, Ami N Shah, Paolo D'Amico, Charles S Dai, Elyssa N Denault, Cynthia X Ma, Seth A Wander, Dejan Juric, Massimo Cristofanilli, Bruce A Chabner, Aditya Bardia
Publikováno v:
Cancer Research. 82:P2-07
Background: Endocrine therapy with CDK 4/6 inhibitors (ET/CDK4/6i) represents the 1st line therapy for ER+/HER2- ABC. While majority of patients derive clinical benefit with combination therapy, a subset have refractory disease with progression withi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::45451e41ea04d68929b99e6bd015bba5
https://doi.org/10.1158/1538-7445.sabcs21-p2-07-02
https://doi.org/10.1158/1538-7445.sabcs21-p2-07-02
Autor:
Lorenzo Gerratana, Rossana Roncato, Mattia Sturlese, Andrew A. Davis, Marko Velimirovic, Carolina REDUZZI, Katherine K. Clifton, Whitney L. Hensing, Ami N. Shah, Charles S. Dai, Paolo D’Amico, Arielle J. Medford, Alessandra Franzoni, Linda Cucciniello, Firas Wehbe, Seth A. Wander, Barbara Belletti, William Gradishar, Amir Behdad, Giuseppe Damante, Cynthia Ma, Fabio Puglisi, Aditya Bardia, Massimo Cristofanilli
Publikováno v:
Cancer Research. 83:PD10-01
Background: ESR1 hotspot mutations (HS) (i.e. 380, 536, 537, and 538) are important drivers of resistance to aromatase inhibitors, but the differential impact of genomic variants (HS vs non-HS) on response to endocrine therapies (ET) under clinical d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2654d278eb73c9b4153d1d7076b87c70
https://doi.org/10.1158/1538-7445.sabcs22-pd10-01
https://doi.org/10.1158/1538-7445.sabcs22-pd10-01
Autor:
Lorenzo Gerratana, Andrew A Davis, Marko Velimirovic, Katherine Clifton, Whitney L Hensing, Ami N Shah, Charles S Dai, Carolina Reduzzi, Paolo D’Amico, Qiang Zhang, Firas Wehbe, Seth Wander, William J Gradishar, Amir Behdad, Fabio Puglisi, Cynthia X Ma, Aditya Bardia, Massimo Cristofanilli
Publikováno v:
Cancer Research. 82:PD6-08
Background: High throughput genomic technologies such as NGS are enhancing the ability to dynamically characterize MBC but their role in describing biological evolution of multiple mutations together remains unclear. ESR1 and PIK3CA are central mutat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b397f4484286aad274a87b2f14cfaad9
https://doi.org/10.1158/1538-7445.sabcs21-pd6-08
https://doi.org/10.1158/1538-7445.sabcs21-pd6-08
Autor:
Arielle J. Medford, Marko Velimirovic, Andrzej Niemierko, Whitney L. Hensing, Andrew A. Davis, Katherine K. Clifton, Jennifer C. Keenan, Charles S. Dai, Lesli A. Kiedrowski, Ami N. Shah, Lorenzo Gerratana, Laura M. Spring, Leif Ellisen, Robert C. Doebele, Massimo Cristofanilli, Aditya Bardia
Publikováno v:
Cancer Research. 83:P5-02
Background GATA3 mutations (GATA3mut) have been reported in 10-20% of hormone receptor positive (HR+) breast cancers. It has been shown that targeting GATA3mut HR+ breast cancer with MDM2 inhibitors invokes synthetic lethality. MDM2 is an E3 ubiquiti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::baa697fbc7224897cb4502fd25dabc1e
https://doi.org/10.1158/1538-7445.sabcs22-p5-02-07
https://doi.org/10.1158/1538-7445.sabcs22-p5-02-07
Autor:
Jennifer C. Keenan, Arielle J. Medford, Lauren J. Oshry, Baris Boyraz, Charles S. Dai, Lesli A. Kiedrowski, Sofia Menshikova, Anna Butusova, Tasos Gogakos, Rachel Occhiogrosso, Phoebe Ryan, Jochen Lennerz, Laura M. Spring, Beverly Moy, Leif Ellisen, Aditya Bardia
Publikováno v:
Cancer Research. 83:P5-02
Introduction: Tissue-agnostic indications for targeted therapies are expanding options for patients with advanced solid tumors. The FDA approvals of the PD-1 inhibitor pembrolizumab and the TRK inhibitors larotrectinib and entrectinib provide rationa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e7a48f1db21e6cd87b1fe8380f69a258
https://doi.org/10.1158/1538-7445.sabcs22-p5-02-13
https://doi.org/10.1158/1538-7445.sabcs22-p5-02-13
Autor:
Whitney L Hensing, Lorenzo Gerratana, Katherine Clifton, Marko Velimirovic, Ami Shah, Paolo D'Amico, Carolina Reduzzi, Qiang Zhang, Charles S Dai, Nusayba A Bagegni, Mateusz Opyrchal, Foluso O Ademuyiwa, Bose Ron, Amir Behdad, Cynthia X Ma, Aditya Bardia, Massimo Cristofanilli, Andrew A Davis
Publikováno v:
Cancer Research. 82:P2-01
Introduction: Approximately 40-50% of breast cancers are characterized by low HER2 expression (HER2-low), defined as immunohistochemistry (IHC) 1+ or 2+ and HER2 fluorescence in situ hybridization (FISH) unamplified, encompassing a large and heteroge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bce3b141e50f7c758be9d910798a715e
https://doi.org/10.1158/1538-7445.sabcs21-p2-01-01
https://doi.org/10.1158/1538-7445.sabcs21-p2-01-01